60 results about "Aminoacid transport" patented technology

The present invention provides a method of improving efficiency of a fermentative production of an L-amino acid. To be specific, the present invention provides a process for producing a L-amino acid, comprising culturing a microorganism wherein the activity of the protein described in any one of (1) to (3) below is higher than that of the parent strain in a medium to produce the L-amino acid and accumulate the L-amino acid in the medium, and then collecting the L-amino acid from the medium:(1) a protein comprising the amino acid sequence shown by any one of SEQ ID NOS:2, 4, 6 and 8(2) a protein consisting of the amino acid sequence resulting from deletion, substitution or addition of one or more amino acids in the amino acid sequence shown in any one of SEQ ID NOS:2, 4, 6 and 8, and having L-amino acid transport activity(3) a protein consisting of the amino acid sequence having 80% or more homology to the amino acid sequence shown in any one of SEQ ID NOS:2, 4, 6 and 8, and having L-amino acid transport activity.

The invention discloses application of an amino acid transporter gene OsAAP3 in rice seed selection, and belongs to the technical field of genetic engineering. An amino acid sequence of encoded protein of the gene OsAAP3 is specified in SEQ ID NO.1, and a Cdna sequence is specified in SEQ ID NO.2. According to the application of the amino acid transporter gene OsAAP3 in rice seed selection, by constructing a rice plant which is interfered by the gene OsAAP3, and constructing a rice plant which is over-expressed by the gene OsAAP3, it is discovered that reduction of genetic expression of the gene OsAAP3 can increase tiller number of the rice and spike number in each rice plant, and therefore the gene OsAAP3 can be used in rice seed selection for increasing the rice yield. The gene OsAAP3 has important application value in expounding influence of amino acid transportation on growth and development process of the plant.

The invention discloses application of the amino acid transport gene OsAAP4 to rice breeding and belongs to the field of plant genetic engineering. The amino acid sequence of OsAAP4 gene encoded protein is as shown in SEQ ID NO.1. The cDAN sequence is as shown in SEQ ID NO.2. By establishing a rice OsAAP4 gene overexpression plant and an OsAAP4 gene interference plant, it is found that the normal rice tiller number and the panicle number of each plant can be increased through improvement of OsAAP4 gene expression, and accordingly the OsAAP4 gene can be used in rice breeding to increase the rice yield. The OsAAP4 gene has important application value in the aspect of stating influences of amino acid transport on plant growth and development process.

The invention discloses application of amino acid transport gene OsAAP1to promotion of rice growth in low nitrogen, belonging to the field of plant genetic engineering. Amino acid of the OsAAP1 gene coding protein and cDNA sequence thereof is shown as following SEQID NO.1, 2. The rice root length, root number, plant height and tiller number can be increased and biomass and yield can be improved by improving the OsAAP1 gene expression in low nitrogen through establishing the rice OsAAP1 overexpression plant. The rice root length, root number, plant height and tiller number can be reduced by decreasing the OsAAP1gene expression through establishing interfering plants. Thereby, the OsAAP1gene can be applied in improving the biomass and the yield of the rice in low nitrogen. The OsAAP1 gene has important application in the respect of rice tolerance to low or poor soil or farmland, reduction of chemical fertilizer usage amount and the rice breed improvement.

The invention relates to preparation of glutamic acid-polyethylene glycol monostearate and application of the amphipathic target material modified nano-particles in disease target transfer. According to the amphipathic target material, glutamic acid is used as a target head, polyethylene glycol is used for improving the flexibility of the target head, and hydrophobic monostearate is used as an anchoring position with polyglycolic-polylactic acid copolymer. The target material modified nano-particles can be used as a target transfer tool of multiple anti-tumor drugs, and interacts with high-expression big neutral amino acid transporter 1 on a tumor cell membrane by the surface modified glutamic acid, so that the cell uptake and anti-tumor activity of the nano-particles can be effectively improved. The nano-particles have good stability, excellent target performance, can be used in intravenous injection, and have a relatively large market application prospect.

The invention discloses an application of an amino acid transport gene OsAAP5 to rice breeding, and belongs to the field of plant gene engineering. An amino acid sequence of a protein encoded by the gene OsAAP5 is shown in SEQ ID NO.1, and a cDNA sequence is shown in SEQ ID NO.2. By constructing the rice gene OsAAP5 for plant interference, it is discovered that the root length, root number, plant height and fresh weight of normal rice can be increased by reducing expression of the gene OsAAP5, so that the gene OsAAP5 can be used in the rice breeding to facilitate rice growth and increase rice biomass. The gene OsAAP5 has an important application value in the aspect of describing the influence of amino acid transport on the plant growth and development process.

The invention relates to an amphiphilic targeting functional material based on high expression of tumor amino acid transporter ATB<0, +> and an application of nano preparation modified by the same in targeting therapy of tumor. In the amphiphilic targeting functional material, stearic acid (SA) serves as a hydrophobic end while amino acid (AA) serves as a target end, and the middle connection bridge is polyethylene glycol (PEG). The nano preparation modified by the amphiphilic targeting functional material can remarkably improve the tumor targeting ability of an active drug. The characteristics of the invention are that the targeting functional material is easy to prepare, and the nano preparation modified by the targeting functional material can actively target the amino acid transporter ATB<0, +> with high expression of tumor, has high biocompatibility and can remarkably improve the drug therapeutic effect.

The invention discloses a nutritional adsorbent used for relieving pigling mycotoxin poisoning. The nutritional adsorbent is composed of, by mass, 4 to 5% of vitamin E, 10.08 to 12% of sodium butyrate, 11 to 12% of astragalus polysaccharide, 20 to 30% of glucomannan, and 42 to 53% of HSCAS. The intestinal nutritional agent is capable of providing enterocytes with nutrients, so that under mycotoxin stressed conditions, the nutritional adsorbent is beneficial for protection of structural and functional completeness via intestinal mucosa rapid repairing, is capable of promoting transportation and absorption of glucose and amino acid, and reducing feed conversion ratio obviously; the nutritional adsorbent is capable of increasing pigling intestinal antioxidant capacity, and relieving intestinal oxidative damage caused by mycotoxin; the nutritional adsorbent is used for maintaining intestinal health via adjusting pigling intestinal flora; and excellent improvement effects on poisoning caused by a plurality of mycotoxins are achieved via nutrition regulation.

The invention discloses an intestinal tract nutrient capable of alleviating the mycotoxicosis of piglets. The intestinal tract nutrient comprises the following components with contents in percentage by mass: 12.6-17% of sodium butyrate, 3-4% of glutamine, 9-10% of astragalus polysaccharide, 0.1-0.4% of lactobacillus, 9.17-10% of bacillus subtilis and 58.6-63% of rice bran and hull. The intestinal tract nutrient disclosed by the invention is beneficial to rapidly repair and protect the structural and functional integrity of intestinal mucosa under a mycotoxin stress condition by reinforcing enterocyte nutrition, promoting the transportation and absorption of glucose and amino acids, and remarkably reducing the feed conversion rate; the product disclosed by the invention is also capable of improving the intestinal tract antioxidative capacity of the piglets, and alleviating the intestinal tract oxidative damages caused by mycotoxins; the product disclosed by the invention is capable of maintaining the intestinal tract healthy by adjusting the intestinal tract floras of the piglets; the product disclosed by the invention is good in improvement effect on multiple mycotoxicosis symptoms through nutrition regulation means.

A human N system amino acids transporter (hNAT-1), its coding sequence, its preparing process and its use are disclosed. The nucleic acid and antisence strand or fragment of said hNAT-1 can be used to prepare the probe for detecting the abnormality of hNAT-1 gene. The hNAT-1 protein or its suppressor can be used to prepare medicines or reagent kit for regulating the bioactivity of living body, especially the liver cells.

The invention relates to space microbacterium oxydans LCT-H6, in particular to a space microorganism which is obtained through separation of condensed water in a 'Shenzhou 9' spacecraft return capsule with a space technology. The space microbacterium oxydans LCT-H6 is characterized in that microbacterium oxydans LCT-H6 is an aerobic gram-positive bacterium, has the closest genetic relationship with microbacterium maritypicum, and the space microbacterium oxydans LCT-H6 has corrosion capability for four polymer materials including epoxy resin, ester type polyurethane, ether type polyurethane and vulcanized natural rubber. The space microbacterium oxydans LCT-H6 is clarified on the level of genomics, the total length of a whole genome sequence of LCT-H6 proves to be 4.11 Mbp, the content of GC is 67.65%, protein of the space microbacterium oxydans LCT-H6 is classified and noted as the class-22 COG family, and COG containing a largest amount of protein has functions on 'energy generation and conversion', 'amino acid transportation and metabolism', 'sugar transportation and metabolism', 'inorganic salt ion transportation and metabolism' as well as 'translation, ribosome structure and forming'.

The present invention is based in part on the discovery of brown and white fat cell specific surface markers. It has been found that the small amino acid transporter Slca10 / Asc1 is a specific surface marker for white adipocytes and that the ligand-gated ion channel P2X5 and the small amino acid transporter Slc36a2 are specific surface markers for brown adipocytes. Having identified these specific white and brown cell surface markers, the present invention provides compositions and methods suitable for the targeting of any number of agents to a white or brown adipose tissue and the identification and isolation of white or brown adipocytes for any number of uses including therapeutic, screening and diagnostic purposes.

The present invention has revealed the compounds transportable by ATB<0+>. Based on the information about these compounds, drugs transportable by ATB<0,+> may be designed, produced and screened. Such drugs may serve to treat and / or prevent the diseases in which NOS, phenylglycine, carnitine, D-amino NOS, phenylglycine, carnivolved. The ATB<0,+> gene may be administered to patients to be used for gene therapy of the diseases as described above.

The invention belongs to the technical field of tobacco genome gene function analysis, and particularly relates to application of a tobacco NtAAP3 gene in tobacco. The tobacco NtAAP3 is related to amino acid transport, and after the tobacco NtAAP3 is silenced, the contents of tyrosine, proline and asparagine in tobacco are obviously reduced, and the total protein content is obviously reduced; and on the other hand, the tobacco NtAAP3 gene is related to adjustment of the content of pigment substances in tobacco, and after the tobacco NtAAP3 gene is silenced, the content of the pigment substances such as chlorophyll a / b, total chlorophyll and carotenoid in tobacco leaves is obviously increased. According to the application, the relationship between the NtAAP3 gene and amino acid regulation, protein content regulation and pigment content regulation is preliminarily determined, and a theoretical foundation is laid for elaborating the functions of the NtAAP3 gene in the aspects of absorption and transport of amino acid, nitrogen utilization, regulation of plant stress resistance and the like.

A novel amino acid transporter molecule mediating transportation of amino acids, which are nutrients essentially required in the survival and proliferation of various normal cells constituting a living body and various pathology-associated abnormal cells such as tumor cells, into cells and being expressed specifically in tumor cells compared with normal cells; and drugs for treating various pathogenic conditions such as tumor (cancer) which are obtained by identifying and isolating the above amino acid transporter molecule and identifying a substance capable of inhibiting the biological activity and / or expression of this molecule. Intensive studies were made to identify a tumor cell membrane surface molecule associating or interacting with a cell membrane surface 4F2hc molecule seemingly playing an important role in the activation of an unknown amino acid transporter. As a result, a gene encoding the novel amino acid transporter molecule, which mediates the incorporation of various neutral amino acids, various drugs or physiological substances into cells, has been found out and a substance capable of inhibiting the incorporation of amino acids via this molecule and thus inhibiting the proliferation of tumor cells has been also found out.

A novel amino acid transporter molecule mediating transportation of amino acids, which are nutrients essentially required in the survival and proliferation of various normal cells constituting a living body and various pathology-associated abnormal cells such as tumor cells, into cells and being expressed specifically in tumor cells compared with normal cells; and drugs for treating various pathogenic conditions such as tumor (cancer) which are obtained by identifying and isolating the above amino acid transporter molecule and identifying a substance capable of inhibiting the biological activity and / or expression of this molecule. Intensive studies were made to identify a tumor cell membrane surface molecule associating or interacting with a cell membrane surface 4F2hc molecule seemingly playing an important role in the activation of an unknown amino acid transporter. As a result, a gene encoding the novel amino acid transporter molecule, which mediates the incorporation of various neutral amino acids, various drugs or physiological substances into cells, has been found out and a substance capable of inhibiting the incorporation of amino acids via this molecule and thus inhibiting the proliferation of tumor cells has been also found out.

The present invention provides a method of improving efficiency of a fermentative production of an L-amino acid. To be specific, the present invention provides a process for producing a L-amino acid, comprising culturing a microorganism wherein the activity of the protein described in any one of (1) to (3) below is higher than that of the parent strain in a medium to produce the L-amino acid and accumulate the L-amino acid in the medium, and then collecting the L-amino acid from the medium:(1) a protein comprising the amino acid sequence shown by any one of SEQ ID NOS:2, 4, 6 and 8(2) a protein consisting of the amino acid sequence resulting from deletion, substitution or addition of one or more amino acids in the amino acid sequence shown in any one of SEQ ID NOS:2, 4, 6 and 8, and having L-amino acid transport activity(3) a protein consisting of the amino acid sequence having 80% or more homology to the amino acid sequence shown in any one of SEQ ID NOS:2, 4, 6 and 8, and having L-amino acid transport activity.

The invention provides a therapeutic agent for autoimmune diseases, particularly type 1 diabetes and rheumatoid arthritis, as well as a method of preparing the therapeutic agent and a method of treating an autoimmune disease with the therapeutic agent. The therapeutic agent is an anti-CD98 antibody that does not inhibit amino acid transport of CD98 but has a suppressive action on T lymphocyte activation, a suppressive action on cell adhesion mediated by fibronectin, as well as an OVA antibody production suppressive action in OVA immunization model.

The invention belongs to the technical field of pharmaceuticals and particularly relates to a stomach-cancer-resistant composition and an application thereof. The stomach-cancer-resistant composition disclosed by the invention is characterized by comprising 140-180 parts of ginseng, 15-30 parts of Chinese actinidia flowers, 30-80 parts of nightshade and 60-120 parts of semen aesculi. The invention also provides the application of the composition to preparation of stomach-cancer-resistant drugs. The stomach-cancer-resistant composition has the beneficial effects that experiments prove that the drugs respectively have an efficient anti-cancer effect; and 2, the anti-cancer mechanism of the drugs is possible as follows: the transportation function of an L-amino acid transporter 1 is inhibited by effective ingredients in the drugs, so that a favorable anti-cancer effect is achieved.

The invention belongs to the technical field of pharmaceuticals and particularly relates to a colon-cancer-resistant composition and an application thereof. The colon-cancer-resistant composition disclosed by the invention is characterized by comprising 100-150 parts of ginseng, 45-80 parts of sophora fruits, 40-90 parts of Chinese actinidia roots and 70-110 parts of ficus carica. The colon-cancer-resistant composition has the beneficial effects that experiments prove that 1, drugs respectively have an efficient anti-cancer effect; and 2, the anti-cancer mechanism of the drugs is possible as follows: the transportation function of an L-amino acid transporter 1 is inhibited by effective ingredients in the drugs, so that a favorable anti-cancer effect is achieved.

The invention discloses application of amino acid transport gene OsANT1 in paddy rice breeding, and belongs to the field of plant gene engineering. The amino acid sequence of the OsANT1 gene encoded protein is shown as SEQ ID NO. 1, and the sequence of cDNA is shown as SEQ ID NO. 2. The increase of OsANT1 gene expression is discovered by constructing an overexpression plant of paddy rice OsANT1 gene, and the root length, the root quantity, the plant height and the fresh weight of normal paddy rice can be increased, so that the biomass is improved. The decrease of OsANT1 gene expression is discovered by constructing interference plants, and the root length, the root quantity and the fresh weight of normal paddy rice can be decreased. Therefore, the OsANT1 gene can be used for promoting the growth of paddy rice and increasing the biomass of paddy rice in paddy rice breeding. The OsANT1 gene has significant application values in the aspects of explaining plant growth and development process influenced by amino acid transportation.

The invention discloses a sulfonyl fluoride compound. Compared with reported PET imaging agents for targeted amino acid transporter, fibroblast activating protein, vesicular monoamine transporter 2, serotonin receptor and prostate specific membrane antigen protein change related diseases, the series of sulfonyl fluoride compounds designed and synthesized by the invention have the advantages of simple labeling conditions, high yield and high affinity. The invention belongs to the technical field of radiopharmaceutical chemistry and nuclear medicine.

The present invention describes the synthesis of biological samples that can be used for the purpose of enhancing the signal-to-noise ratios achievable during the imaging of protein synthesis, amino acid transport and neurotransmitter transport, particularly in applications where single-molecule resolution is demanded. The present invention provides quencher-labeled elongation factor (EF-Tu) and fluorophore-labeled tRNA. When these molecules are present in a ternary complex with GTP, the fluorescently-labeled tRNA is quantitatively quenched. Once the tRNA is incorporated into an actively translating ribosome, however, a burst of fluorescence is released and can be detected by a variety of techniques, including smFRET imaging. The invention further provides novel EF-Tu constructs for achieving quencher labeling at high levels while retaining native or near native activity in the translation reactions, as well as methods for preparing stable ternary complexes, methods of protein sequencing, methods of detecting amino acid transport using a proteoliposome assay system and the proteoliposomes systems and methods of imaging translation events in single living cells. The present invention should have an immediate impact on next-generation sequencing technologies and the detection of neurotransmitter transporter activities in both in vitro and in vivo settings, a critical component of drug activity / screening assays targeting this important class of molecules.

Disclosed is a novel therapeutic agent for autoimmune diseases, particularly type-1 diabetes and rheumatoid arthritis. A novel anti-CD98 antibody can be produced, and a novel therapeutic agent for autoimmune diseases (type-1 diabetes and rheumatoid arthritis) which relies on a novel mechanism of action can be provided using the antibody. The novel anti-CD98 antibody does not inhibit the transport of an amino acid by CD98. Further, unlike conventional anti-CD98 antibodies, the novel anti-CD98 antibody has activities such as an inhibitory activity on the activation of T-lymphocytes, an inhibitory activity on fibronectin-mediated cell adhesion, and an inhibitory activity on the production of an OVA antibody in an OVA-sensitized model.

A novel amino acid transporter molecule mediating transportation of amino acids, which are nutrients essentially required in the survival and proliferation of various normal cells constituting a living body and various pathology-associated abnormal cells such as tumor cells, into cells and being expressed specifically in tumor cells compared with normal cells; and drugs for treating various pathogenic conditions such as tumor (cancer) which are obtained by identifying and isolating the above amino acid transporter molecule and identifying a substance capable of inhibiting the biological activity and / or expression of this molecule. Intensive studies were made to identify a tumor cell membrane surface molecule associating or interacting with a cell membrane surface 4F2hc molecule seemingly playing an important role in the activation of an unknown amino acid transporter. As a result, a gene encoding the novel amino acid transporter molecule, which mediates the incorporation of various neutral amino acids, various drugs or physiological substances into cells, has been found out and a substance capable of inhibiting the incorporation of amino acids via this molecule and thus inhibiting the proliferation of tumor cells has been also found out.

The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.

The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.

A mixed amino acid metal salt complex of the mixed amino acids, lysine and glutamic acid associated with trace metals selected from the group consisting of iron, manganese, copper and zinc to provide highly bioavailable sources of the iron, manganese, copper and zinc and as well to take advantage of the different amino acid transport pathways of lysine and glutamic acid.

The invention belongs to the technical field of pharmaceuticals and particularly relates to a lung-cancer-resistant composition and an application thereof. The lung-cancer-resistant composition disclosed by the invention is characterized by comprising 160-200 parts of ginseng, 50-90 parts of radix adenophorae and 60-120 parts of oldenlandia diffusa. The invention also provides the application of the composition to preparation of lung-cancer-resistant drugs. The lung-cancer-resistant composition has the beneficial effects that experiments prove that the drugs respectively have an efficient anti-cancer effect; and 2, the anti-cancer mechanism of the drugs is possible as follows: the transportation function of an L-amino acid transporter 1 is inhibited by effective ingredients in the drugs, so that a favorable anti-cancer effect is achieved.